Amends current law on controlled substances to permit psilocybin to be cultivated within a person's residence for personal use and contingent on the US FDA's program, mandate that RI department of health establish rules regulations.
H5186 would create a limited exemption in Rhode Island’s Uniform Controlled Substances Act for psilocybin. Under the bill, possession or sharing of less than one ounce of psilocybin would not be subject to the chapter’s prohibitions, and a person could also securely cultivate psilocybin in their residence for personal use. The measure is framed as a narrow change to state drug law rather than a broad legalization scheme, and it is set to expire on July 1, 2027.
The bill also anticipates future federal action. If the U.S. Food and Drug Administration reschedules psilocybin, the Rhode Island Department of Health would be required to adopt rules governing cultivation, distribution, and medical prescribing. Separately, if the FDA expands its access program, patients with serious or life-threatening mental or behavioral health disorders who lack effective treatment options could access psilocybin at department-approved locations in Rhode Island. The bill would take effect July 1, 2025, and requires reports before sunset from the attorney general and the health department on enforcement activity and federal developments.
If enacted, H5186 would amend chapter 21-28 of the General Laws by carving out a psilocybin-specific exemption from the state’s controlled substances framework. It would reduce criminal exposure for limited possession, sharing, and home cultivation of psilocybin, while preserving state oversight for any future regulated medical or distribution system tied to federal rescheduling or expanded FDA access. The bill would also create reporting obligations for the attorney general and the director of health, and its sunset date would limit the duration of the change unless renewed or replaced.
The bill appears to reflect a reform-oriented, exploratory approach to psilocybin policy, with sponsors seeking to move Rhode Island toward limited personal use and possible medical access. Because there are no committee transcripts or recorded votes provided, there is no documented debate or formal vote history to indicate broader legislative sentiment. Based on the text alone, the measure is cautious in structure, using thresholds, federal contingencies, and a sunset date to frame the policy as a temporary pilot rather than a permanent overhaul.
The main points of contention likely concern drug policy, public health, and the timing of state action ahead of federal changes. Supporters would likely emphasize personal autonomy, potential mental health benefits, and a controlled pathway for future medical use. Opponents would likely focus on controlled-substance enforcement, safety, diversion risks, and the appropriateness of allowing home cultivation or possession before federal rescheduling. The bill’s reliance on FDA action and its short sunset suggest an attempt to balance those competing concerns.